Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Wellgistics Health (WGRX) Cash from Financing Activities (2024 - 2025)

Wellgistics Health filings provide 2 years of Cash from Financing Activities readings, the most recent being $2.4 million for Q4 2025.

On a quarterly basis, Cash from Financing Activities rose 14.89% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.8 million, a 503.0% increase, with the full-year FY2025 number at $10.8 million, up 503.0% from a year prior.
Cash from Financing Activities hit $2.4 million in Q4 2025 for Wellgistics Health, down from $5.2 million in the prior quarter.
In the past five years, Cash from Financing Activities ranged from a high of $5.2 million in Q3 2025 to a low of -$538037.0 in Q2 2024.